Página principal > Resultados de la búsqueda: Cell- and Tissue-Based Therapy
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 4 registros encontrados en 0.02 segundos.
Artículos, Encontrados 4 registros
Artículos Encontrados 4 registros  
1.
10 p, 2.6 MB Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies / García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ; Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ; Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ; Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ; Locatelli, Franco (Sapienza University of Rome) ; Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ; Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ; Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Urdinguio, Rocío G. (Universidad de Oviedo) ; Fernandez, A.F. (Universidad de Oviedo) ; Fraga, Mario F. (Universidad de Oviedo) ; Bar, Diana (The Edmond and Lily Safra Children's Hospital) ; Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ; Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ; Besser, MichalJ. (Tel Aviv University) ; Avigdor, Abraham (Sheba Medical Center) ; Jacoby, Elad (Tel Aviv University) ; Esteller, M (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 - 10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445  
Registro completo - Creative Commons
2.
13 p, 705.8 KB Current landscape of clinical development and approval of advanced therapies / Iglesias-Lopez, Carolina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ; Vallano, Antoni (Servei Català de la Salut) ; Obach, Mercè (Servei Català de la Salut)
Advanced therapy medicinal products (ATMPs) are innovative therapies that mainly target orphan diseases and high unmet medical needs. The uncertainty about the product's benefit-risk balance at the time of approval, the limitations of nonclinical development, and the complex quality aspects of those highly individualized advanced therapies are playing a key role in the clinical development, approval, and post-marketing setting for these therapies. [...]
2021 - 10.1016/j.omtm.2021.11.003
Molecular Therapy. Methods & Clinical Development, vol.23 (november 2021) p. 606-618  
Registro completo - Creative Commons
3.
9 p, 925.7 KB The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction : the BAMI trial / Mathur, Anthony (Centre for Cardiovascular Medicine & Devices, Queen Mary University of London) ; Fernández Avilés, F. (Hospital General Universitario Gregorio Marañón) ; Bartunek, Jozef (Cardiovascular Center, OLV Hospital Aalst) ; Belmans, Ann (KU) ; Crea, Filippo (Fondazione Policlinico Universitario A. Gemelli IRCCS) ; Dowlut, Sheik (Centre for Cardiovascular Medicine & Devices, Queen Mary University of London) ; Galiñanes, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Good, Marie-Claire (Queen Mary University of London) ; Hartikainen, Juha (Kuopio University Hospital ( Finlàndia)) ; Hauskeller, Christine (University of Exeter) ; Janssens, Stefan (University Hospitals Leuven (Bèlgica)) ; Kala, Petr (University Hospital Brno (República Txeca)) ; Kastrup, Jens (University of Copenhagen) ; Martin, John (University College London) ; Menasché, Philippe (Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou and University of Paris) ; Sanz-Ruiz, Ricardo (Hospital General Universitario Gregorio Marañón) ; Ylä-Herttuala, Seppo (University of Eastern Finland) ; Zeiher, Andreas Michael (Department of Medicine III, Goethe University of Frankfurt) ; Universitat Autònoma de Barcelona
Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients following acute myocardial infarction (AMI), though existing trial results are inconsistent. Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ventricular ejection fraction (LVEF, ≤45%) after primary angioplasty (PPCI) for ST-elevation AMI. [...]
2020 - 10.1093/eurheartj/ehaa651
European heart journal, Vol. 41 (august 2020) , p. 3702-3710  
Registro completo - Creative Commons
4.
14 p, 7.7 MB Regulatory framework for advanced therapy medicinal products in Europe and United States / Iglesias-Lopez, Carolina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ; Obach, Mercè ; Vallano, A. (Servei Català de la Salut)
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The European Union (EU) and the United States (US) are fostering their development. For both regions, ATMPs fall under the regulatory framework of biological products, which determines the legal basis for their development. [...]
2019 - 10.3389/fphar.2019.00921
Frontiers in Pharmacology, Vol. 10 Núm. JULY (2019) , p. 921  
Registro completo - Creative Commons

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos